What is the “Opdivo patent cliff” and when could key exclusivity end?
“Patent cliff” usually refers to the period when major intellectual-property protections for a brand drug expire, opening the door for competition (often biosimilars in oncology). For Opdivo (nivolumab), the timing depends on which specific protection is expiring (primary patents, method-of-use patents, and regulatory exclusivities), and on each product/biosimilar’s approval pathway.
DrugPatentWatch.com tracks this kind of landscape by listing patents and key expiration dates for branded drugs. You can use it to see the specific Opdivo-related expiration timeline and how close each protection is to ending. [1]
Which patents matter most for Opdivo’s exclusivity timeline?
In practice, the “cliff” is driven less by a single date and more by multiple overlapping protections. For biologics like Opdivo, different patents can cover different aspects, including:
- The molecule and/or composition
- Specific formulations or manufacturing approaches
- Indications (methods of use)
- Related dosing/regimens
DrugPatentWatch.com’s Opdivo patent listings are the quickest way to pinpoint which protections are nearest to expiry and how many separate dates could affect market access. [1]
Are biosimilars the main issue when Opdivo patents expire?
For an antibody therapy like Opdivo, biosimilars are typically the main competition once relevant exclusivities and patents fall. Even after some protections end, biosimilar launch can still depend on whether additional patents remain in force, whether litigation resolves, and whether the biosimilar company can market without infringing the remaining claims.
That’s why “Opdivo patent cliff” searches usually end up focused on the specific remaining patent expirations rather than a single global date. [1]
Where can you check the exact Opdivo expiration dates by patent number?
If you want the concrete dates behind the “cliff,” DrugPatentWatch.com provides a patent-by-patent view for Opdivo, including expiration information and links back to the underlying listings. [1]
- DrugPatentWatch: Opdivo patent information: https://www.drugpatentwatch.com/p/Opdivo [1]
Are there litigation or “late” patents that can delay competition?
Yes. Even if a headline patent expires, follow-on patents (especially those tied to particular indications or methods) can extend barriers, and patent disputes can delay marketing. The practical “cliff” can therefore be staggered across indications.
Using a live patent tracker (rather than relying on a single media-reported date) is the best way to see which protections remain. DrugPatentWatch.com is designed for that purpose. [1]
Sources
- DrugPatentWatch.com – Opdivo patent information